Introduction
The adenomatous polyposis coli gene (APC) at chromosome 5q21 encodes a large multidomain protein with diverse cellular functions and tumour-suppressing activity. Germline APC mutations are responsible for familial adenomatous polyposis, an autosomaldominant precancerous condition characterized by the appearance of multiple adenomatous polyps of the colorectum, and acquired APC mutations have been found in the majority of sporadic colorectal cancers (Fodde, 2002) . A more widespread role of APC in human cancer has been suggested by the demonstration of APC mutations in hepatoblastomas and in gastric, pancreatic, thyroid, breast, and ovarian cancers, albeit at rates significantly lower than in colorectal tumours (Horii et al., 1992a, b; Zeki et al., 1994; Oda et al., 1996; Furuuchi et al., 2000; Wu et al., 2001) . Moreover, transcriptional silencing of APC by promoter hypermethylation, a potential alternative mechanism of gene inactivation, has been found in a variety of human malignancies, with particularly high rates in oesophageal, gastric, breast, lung, and endometrial cancers (Hiltunen et al., 1997; Esteller et al., 2000; Kawakami et al., 2000; Tsuchiya et al., 2000; Virmani et al., 2001; Moreno-Bueno et al., 2002; Usadel et al., 2002) .
The best-known function of the APC protein is in the regulation of cellular b-catenin, a key effector in the canonical Wnt signalling transduction pathway (Giles et al., 2003) . In normal cells, the largest fraction of bcatenin is complexed with E-cadherin at the cell membrane. In the absence of an appropriate Wnt signal, free b-catenin binds to a destruction complex consisting of APC, axin, and glycogen synthase kinase 3b (GSK3b), and is marked for ubiquitylation and subsequent proteasomal degradation through GSK-3b-mediated phosphorylation. Upon Wnt signalling, the activity of GSK-3b is inhibited through a poorly understood signalling cascade. In the absence of GSK-3b activity, b-catenin accumulates in the cytoplasm and shuttles to the nucleus where it acts as an essential transcriptional coactivator of proteins of the T-cell factor (Tcf)/ lymphoid enhancer factor (Lef) family. Genes involved in malignant transformation have been identified as key transcriptional targets of the Wnt signalling pathway, including the genes encoding c-Myc and cyclin D1 (He et al., 1998; Tetsu and McCormick, 1999) .
Several lines of evidence have implicated dysregulated Wnt signalling in the development of cutaneous malignant melanoma. First, nuclear and/or cytoplasmic localization of b-catenin, a potential indicator of Wnt pathway activation, has been found in approximately one-third of melanoma specimens (Rimm et al., 1999; Omholt et al., 2001; Demunter et al., 2002) . Second, Rubinfeld et al. (1997) ) at the N-terminal domain of b-catenin, rendering b-catenin resistant to degradation by the ubiquitin-proteasome pathway. In two additional melanoma cell lines, Rubinfeld et al. (1997) found loss or alteration of the APC protein, suggesting that dysregulated Wnt signalling in melanoma also can be caused by alterations of the APC gene. To further assess the role of Wnt signalling in melanoma, in particular the role of APC, we examined 40 melanoma cell lines for activating CTNNB1 mutations, mutations in the entire coding region and all consensus splice sites of APC, and hypermethylation of APC promoter 1A. The impact of CTNNB1 and APC alterations on Wnt signalling was evaluated through determination of the activity of endogenous and ectopic b-catenin/Tcfresponsive target genes. In addition, the impact of reduced APC expression on the proliferation and invasive growth of melanoma cells was evaluated by RNA interference (RNAi) experiments.
Results

CTNNB1 and APC mutations in melanoma cell lines
To identify molecular alterations of the APC/b-catenin pathway in malignant melanoma, we first examined 40 melanoma cell lines for activating b-catenin mutations. Denaturing gradient gel electrophoresis (DGGE) analysis of CTNNB1 exon 3, which encodes the N-terminal phosphorylation sites of b-catenin, revealed one cell line (FM9) with a band shift. Sequence analysis of this sample revealed a GAC to GGC transition at codon 32, leading to the substitution of aspartic acid with glycine (data not shown). Immunoblot analysis showed increased levels of b-catenin in this cell line (data not shown), consistent with previous data showing cellular accumulation of b-catenin in hepatocellular carcinomas with CTNNB1 mutations affecting codon 32 (Miyoshi et al., 1998) .
We next examined the entire coding region and all consensus splice sites of APC by DGGE in the same panel of melanoma cell lines (Figure 1 ). Six different sequence variants were identified including one nonsense mutation and five missense variants (Table 1) . The nonsense mutation was associated with loss of the corresponding wild-type APC allele (Figure 1a and b) and introduces a premature termination signal at residue 1447 in the mutation cluster region of APC, the most common site of mutation in colorectal cancers (Fodde et al., 2001) . All missense variants were associated with retention of the wild-type allele (data not shown). Two of these variants, H712T and G2502S, were also found The APC gene contains two promoters (1A and 1B) that initiate transcription from distinct sites (exons 1A and 1B). Aberrant methylation of the CpG island in promoter 1A has been reported in a variety of cancers, whereas the CpG island in promoter B is consistently unmethylated (Esteller et al., 2000) . To examine the methylation status of promoter 1A in malignant melanoma, SssI-methylated DNA, and DNA from 40 melanoma cell lines, 54 unrelated melanoma biopsies, and normal cultured melanocytes was treated with sodium bisulphite and amplified with primer pairs specific for methylated and unmethylated APC alleles (methylation-specific PCR, MSP). While normal melanocytes contained only unmethylated APC alleles, APC promoter 1A hypermethylation was present in five (13%) of the cell lines ( Figure 2a) . Three of these cell lines (FM39, FM79, and FM95) contained only methylated alleles, whereas FM91 and SK-MEL-3 showed signals for both methylated and unmethylated alleles ( Figure 2a ). DGGE analysis of SNPs in genomic DNA from FM95 showed retention of both APC alleles (data not shown), suggesting that methylation in this cell line was biallelic. APC hypermethylation was also present in one of 15 (7%) primary melanomas, and eight of 39 (21%) metastases (Figure 2b ; P ¼ 0.42, twotailed Fisher's exact test).
High-resolution APC methylation patterns
To further evaluate the patterns of APC methylation, DNA from the 40 melanoma cell lines was analysed by methylation-specific melting curve analysis (MS-MCA) (Worm et al., 2001b) . A region of APC promoter 1A containing 15 CpG sites was amplified using primers that do not discriminate between methylated and unmethylated alleles, and the PCR products were subsequently subjected to MCA. In concordance with the results of the MSP analysis, the same five cell lines contained methylated APC alleles (for examples, see Figure 3a ). Three of these cell lines (FM39, FM79, and FM95) showed a single peak with an apparent melting temperature (T m ) of B871C, corresponding to the peak obtained with SssI-methylated DNA, suggesting that these cell lines contain completely methylated APC alleles. By contrast, the two cell lines that gave rise to both methylated and unmethylated MSP signals showed different melting curves (Figure 3a) . SK-MEL-3 showed two melting peaks with T m values corresponding to unmethylated and methylated APC alleles, respectively, suggesting that APC methylation in this cell line is allele specific. The melting peak of FM91 was slightly broadened compared with either of the controls and had an overall T m slightly lower than that of the fully methylated sequence, suggesting that this cell line contains heterogeneously methylated APC alleles. Analysis of SNPs in this cell line showed retention of both APC alleles (data not shown). To further resolve the methylation pattern in FM91, the methylation status of 28 CpG sites, ranging from position À306 to þ 117 relative to the transcription start site in APC promoter 1A, was investigated in 50 individual alleles (Figure 3b ). A total of 17 different epigenotypes were identified, of which one accounted for 40% of the clones (Figure 3b ). The methylation densities ranged from 39 to 89%. The CpG sites at positions À275, À139, À82, þ 23, and þ 102 were methylated in all clones ( Figure 3b ).
APC expression in melanoma cell lines
To study how aberrations in DNA methylation may affect expression from APC promoter 1A, we examined 33 of the melanoma cell lines by RT-PCR analysis. All cell lines showed expression of a transcript from exon 11 to exon 14, which represents the combined transcripts from promoters 1A and 1B ( Figure 4a ). A promoter 1A-specific transcript from exon 1A to exon 2 was expressed in all unmethylated cell lines and in SK-MEL-3 cells, which carry monoallelic APC methylation, but was not expressed in any of the three cell lines carrying a completely methylated APC promoter 1A or FM91, which contained heterogeneously methylated APC alleles ( Figure 4a ). These results suggest a direct association between APC promoter 1A methylation and transcriptional silencing. Transcriptional regulation by DNA methylation has been shown to involve changes in histone acetylation (Coffee et al., 1999) . To investigate the roles of DNA methylation and histone acetylation in the control of APC transcription, FM79 cells carrying fully methylated APC alleles were treated with the demethylating agent 5-aza-2 0 -deoxycytidine (5-Aza-Cdr) and the histone deacetylase inhibitor trichostatin A (TSA), alone and in combination. While 5-Aza-Cdr re-activated APC Expression from APC promoters 1A and 1B
Immunoblot analysis using either of two commercially available, monoclonal antibodies raised against the Nterminal domain of APC, F-3 and ab58, only detected a band of the expected size in FM9 cells (data not shown), and thus the possible effect of APC promoter 1A methylation on APC expression levels could not be determined at the protein level. Instead, to examine the levels of expression from APC promoter 1B, we took advantage of the SK-MEL-3 cell line, in which we had found monoallelic mutation (N813S) and monoallelic hypermethylation of promoter 1A. We first determined the allelic distribution of these alterations by examining the site of mutation in a transcript from promoter 1A.
RT-PCR/DGGE analysis of this transcript revealed that only the mutant allele was expressed ( Figure 5 , lane 3), suggesting that promoter 1A had been silenced on the wild-type allele. Because hypermethylation and mutation were on different alleles, we could then estimate the relative contributions from promoters 1A and 1B by analysing the distribution of mutant and wild-type alleles in the combined transcripts. As shown in Figure 5 (lane 6), the intensity of the wild-type band, which represents the expression from promoter 1B, was approximately half the intensity of the mutant band, which represents the combined expression from the two promoters. Assuming that the mutant and wild-type transcripts do not differ in stability, these data suggest that transcripts from promoters 1A and 1B are expressed at similar rates and that methylation of promoter 1A causes a reduction in the total levels of APC transcription.
APC alterations and Wnt signalling
Activating CTNNB1 and truncating APC mutations have been unambiguously associated with increased levels of Wnt signalling in colorectal cancer (Fodde et al., 2001) . We therefore examined the possibility that the various CTNNB1 and APC alterations identified in malignant melanoma could also lead to increased activity through the Wnt signalling pathway. We first examined the expression levels of AXIN2, a direct target of the Wnt pathway, which is transcriptionally upregulated in colon cancer cells carrying CTNNB1 or APC mutations (Yan et al., 2001; Jho et al., 2002; Leung et al., 2002; Lustig et al., 2002) . Highly increased levels of Axin2 transcripts were detected in FM57 cells, which carry a hemizygous APC truncation, and in FM9 cells, which carry an activating CTNNB1 mutation. By contrast, no increases in Axin2 expression levels were found in cell lines harbouring APC promoter 1A methylation or the APC missense variants G2502S and N813S (Figure 6a ). The levels of Wnt signalling were further examined using a Tcf reporter assay, in which plasmids containing three optimal or three mutant Tcfbinding sites upstream of a Luciferase reporter gene (pTOPFLASH and pFOPFLASH, respectively) were cotransfected with a b-galactosidase construct into melanoma cells. As shown in Figure 6b , increased levels of Wnt signalling were detected in FM9 and FM57, but not in cell lines harbouring APC promoter 1A methylation or the APC missense variants G2502S, S130G, and N813S. These data provide evidence that, in contrast to activating CTNNB1 and truncating APC mutations, APC promoter 1A hypermethylation and missense mutations do not lead to increased activity of Tcf/Lefdependent transcription.
APC controls proliferation and invasive growth of melanoma cells
As shown here and in previous studies (Esteller et al., 2000) , hypermethylation of the APC gene impairs transcription from promoter 1A but does not affect transcription from promoter 1B, suggesting that tran- scriptional silencing of promoter 1A may contribute to the development of malignant melanoma by reducing the levels of APC transcription. To elucidate the possible dose-dependent role(s) of APC on Wnt signalling, cell proliferation, and invasive growth, we generated a pSUPER expression construct (Brummelkamp et al., 2002) designed to produce shRNA and target APC transcripts by RNAi (shRNA-APC). One cell line with APC promoter 1A hypermethylation (FM79) and one cell line without detectable APC or CTNNB1 alterations (FM55-M2) were transfected with this construct and a control construct containing a mismatch in the 19-nt APC targeting sequence (mis-shRNA-APC), and then were grown for 3 weeks in the presence of G418. For each of these cell lines, two independent pools of 450 clones expressing shRNA-APC and two independent pools of 450 clones expressing mis-shRNA-APC were propagated for further characterization.
To evaluate the efficiency of RNAi-mediated suppression of APC in FM79 and FM55-M2 cells, we measured the levels of APC transcripts by RQ-PCR. As shown in Figure 7a , stable expression of shRNA-APC reduced the levels of APC transcripts by B80 and 70% in FM79 and FM55-M2 cells, respectively, compared with the parental cell lines. Whereas stable expression of shRNA-APC only led to minor, nonsignificant increases in Wnt signalling (Figure 7b ), the doubling times of FM79 and FM55-M2 cells were decreased by 425%, compared with the corresponding parental cell lines and cells expressing mis-shRNA-APC (Figure 7c) .
Expression of shRNA-APC in FM55-M2 cells did not lead to obvious changes in cell shape and morphology (data not shown). In contrast, FM79 cells stably expressing shRNA-APC were smaller, less elongated, and less adherent than parental FM79 cells and cells expressing mis-shRNA-APC (Figure 8a and b) . To examine the possible effects of APC suppression on invasive growth, parental and shRNA-expressing FM79 and FM55-M2 cells were incubated for 14 days in collagen I. While parental FM79 and FM55-M2 cells and the corresponding cells expressing mis-shRNA-APC showed clear evidence of invasive growth ( Figure  8c and e), cells expressing shRNA-APC formed dense colonies and did not invade the surrounding matrix (Figure 8d and f) . Collectively, the results from these RNAi experiments suggest that a 470% reduction of APC levels in melanoma cells leads to an increase in cell proliferation rate, but also to a reduction in the invasive capacity.
Discussion
The possible role of aberrant Wnt signalling in the pathogenesis of malignant melanoma has been a matter of controversy. Several immunohistochemical studies have shown frequent localization of b-catenin to the cytoplasm/nucleus in primary and metastatic melanomas (Rimm et al., 1999; Omholt et al., 2001; Demunter et al., 2002) , and Rubinfeld et al. (1997) found activating CTNNB1 mutations in approximately one-fourth of melanoma cell lines. However, several later studies have shown low rates (2-8%) of CTNNB1 mutations in melanoma-derived specimens, including primary tumours, metastases, and cell lines (Rimm et al., 1999; Omholt et al., 2001; Demunter et al., 2002; Pollock and Hayward, 2002; Reifenberger et al., 2002) , questioning the existence of a common genetic component responsible for aberrant cellular localization of b-catenin in melanoma. To further address this issue, we examined the status of CTNNB1 and APC in a panel of 40 melanoma cell lines. One of these cell lines carried a CTNNB1 mutation and another carried a truncating APC mutation associated with loss of the corresponding wild-type allele. Reifenberger et al. (2002) found a single missense variant in the mutation cluster region of APC in 37 malignant melanomas, further suggesting that APC truncation is a rare event in the development of melanoma. Hypermethylation of APC promoter 1A was present in B15% of melanoma cell lines and biopsies, and was associated with transcriptional silencing. One cell line showed a heterogeneous methylation pattern consisting of numerous differentially methylated alleles. Transcription from APC promoter 1A was entirely repressed in this cell line, even if as many as 60% of the CpG sites in the promoter were unmethylated in some alleles, suggesting that the overall methylation level may not be the major determinant of transcriptional silencing. A consistent feature of all epigenotypes in this cell line was methylation of five specific CpG sites distributed over APC promoter 1A. In a recent study, partial demethylation of the human HPRT promoter CpG island revealed three CpG sites that were methylated in all nonexpressing clones (Chen et al., 2001 ). These and our data suggest that methylation of specific CpG sites may be critical for maintaining transcriptional silencing of some CpG island-containing promoters. Considering that heterogeneous methylation of tumour suppressor gene promoters is a common feature of many human cancers, awareness of CpG sites that are consistently methylated in transcriptionally inactive genes may be useful in the design of methylation detection assays.
Transcription from a fully methylated APC promoter 1A in melanoma cells could be induced with 5-Aza-Cdr in a concentration-dependent manner. However, TSA alone had no effect on APC expression at concentrations that increased transcription from a known TSAsensitive gene, p21(WAF1) (Xiao et al., 1999) , in the same cells. Moreover, there was no synergistic effect of TSA and 5-Aza-Cdr on APC expression, in contrast to what has been shown for some other genes silenced by promoter methylation (Cameron et al., 1999; Coffee et al., 1999) . These data suggest that inhibition of histone deacetylation is not sufficient to relieve the suppressive effects of DNA methylation on the APC gene, and, accordingly, that DNA methylation is dominant over histone deacetylase activity in forming transcriptionally inactive chromatin. One possible explanation for the insensitivity of hypermethylated APC promoters to TSA is that DNA methylation prevents the binding of one or more transcriptional activators. Alternatively, methylation-dependent transcriptional repression of APC may be mediated by a TSAinsensitive histone deacetylase, similar to those reported in yeast (Carmen et al., 1999) .
Highly increased expression from endogenous and ectopic b-catenin/Tcf-responsive target genes was demonstrated in two melanoma cell lines carrying a truncating APC mutation and an activating CTNNB1 mutation, respectively, consistent with the known effects of these alterations on b-catenin stability and Tcf transactivation (Fodde et al., 2001) . By contrast, cell lines harbouring APC missense variants and/or promoter 1A hypermethylation showed no evidence of increased Wnt signalling. These data suggest that, even though APC is targeted by genetic and epigenetic alterations in more than one-fourth of melanomas, these alterations only rarely lead to increased Wnt signalling. In cell lines with promoter 1A hypermethyla- tion, the most likely explanation for lack of Wnt signalling is retention of APC activity encoded from the unmethylated promoter 1B. Promoter 1A of APC is generally considered the major transcription start site (Esteller et al., 2000) . Nevertheless, in SK-MEL-3 cells carrying monoallelic mutation and methylation-dependent silencing of the wild-type allele, the contribution from promoter 1B was almost similar to that from promoter 1A. Although it is unknown whether this transcription rate represents the basal level of promoter 1B activity in melanocytic cells, or this promoter is upregulated in response to loss of promoter 1A activity, these data suggest that hypermethylation of promoter 1A causes a reduction in APC levels. Lack of Wnt signalling in melanoma cells retaining some residual activity of wild-type APC is consistent with recent data in mice suggesting that the levels of APC must be reduced to below 2% of normal levels to lead to increased levels of b-catenin (Kielman et al., 2002) .
The APC protein carries multiple functions and has been implicated in the regulation of diverse cellular processes, including signal transduction, cell adhesion and migration, microtubule assembly, and chromosome segregation (Fodde, 2003) . Although deregulation of any of these processes may contribute to tumorigenesis, the current view is that the main tumour-suppressing function of APC is contained in its capacity to control intracellular levels of b-catenin (Fodde et al., 2001) . Strong support of this hypothesis has accumulated from studies of colorectal cancer, in which the most common type of APC alteration is truncating mutations invariable associated with increased levels of b-catenin. However, in many other cancers, including melanoma, the prevailing molecular event targeting APC is hypermethylation of promoter 1A, which, according to the data presented here, may have a tumorigenic effect that is independent of the Wnt signalling pathway. Notably, stable suppression of APC transcripts in melanoma cells was insufficient to increase the levels of Wnt signalling, but still led to significant increases in cell proliferation rate. These data suggest a direct effect of APC on cell cycle regulation, in line with previous reports showing that overexpression of APC reduces the proliferation rate of mouse fibroblast NIH3T3 cells (Ishidate et al., 2000) and impedes cell cycle progression from the G0/ G1 to S phase (Baeg et al., 1995; Ishidate et al., 2000) . Reduction of APC levels in melanoma cells also entirely impaired their invasive growth in collagen I, probably reflecting the pivotal role of APC in controlling microtubule dynamics (Zumbrunn et al., 2001 ) and organization (Mogensen et al., 2002) as well as cell polarity and migration (Etienne-Manneville and Hall, 2003) . Thus, while reduced APC expression may be advantageous to tumour cells in terms of increased proliferation, a certain level of APC activity may be required to maintain invasive growth.
Collectively, our data suggest that APC has a tumoursuppressive function(s) in melanocytic cells, which does not involve dysregulation of the Wnt signalling pathway. We propose that methylation-dependent silencing of APC promoter 1A may contribute to the development of malignant melanoma, and possibly other cancers, by reducing APC expression to a level that increases the cell proliferation potential without compromising the invasive capacity.
Materials and methods
Cell lines and clinical samples
Surgically resected specimens from 15 primary and 39 metastatic melanomas were obtained from the Department of Pathology, Rigshospitalet (Copenhagen, Denmark). The FM melanoma cell lines have been described previously (Guldberg et al., 1997) . The melanoma cell lines SK-MEL-3, SK-MEL-24, SK-MEL-28, and SK-MEL-31 were obtained from the American Type Culture Collection (Manassas, VA, USA). Normal cultured melanocytes were purchased from Clonetics (Cambrex, East Rutherford, NJ, USA). Melanoma cells were maintained as monolayers in RPMI 1640 medium with Glutamax I (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum. The frequency of specific APC variants in the general population of Denmark was determined by analysis of 72 genomic DNA samples collected from random, anonymous blood donors. Approval of this study was obtained from the local ethical committee.
5-Aza-CdR and TSA treatment
Cells were plated at 0.5 Â 10 6 /T-25 tissue culture flask in 5 ml of culture medium (day 0) and treated the next day with 5-AzaCdR at final concentrations from 0.5 to 2 mM. At day 3, TSA was added at a final concentration of 0.5 mM. At day 4, cells were harvested by trypsinization, and RNA was isolated for RT-PCR experiments.
Methylation analysis
Genomic DNA was subjected to modification by sodium bisulphite to convert unmethylated cytosines but not methylated cytosines to uracil, as described previously (Worm et al., 2001b) . Normal lymphocyte DNA treated with SssI methyltransferase (New England Biolabs, Beverly, MA, USA) served as the methylated control. For MSP analysis of APC promoter 1A (GenBank accession no. AC008575), the primers for the unmethylated reaction were 5 0 -GTGTTTTATTGTG GAGTGTGGGTT-3 0 and 5 0 -CCAATCAACAAACTCC CAACAA-3 0 , which amplify a 108-bp product (positions 27098 to 27205), and the primers for the methylated reaction were 5 0 -TATTGCGGAGTGCGGGTC-3 0 and 5 0 -TCGAC-GAACTCCCGACGAA-3 0 , which amplify a 98-bp product (positions 27104 to 27201). PCR was carried out at an annealing temperature of 601C, using the HotStarTaq Kit (Qiagen, Valencia, CA, USA). For MS-MCA analysis, the primers were 5 0 -[CGCC]-TGGGAGGGGTTTTGTGTTTTA TT-3 0 and 5 0 -[CGCCCGCCGCGCCCCGCGCCCGTCCCG CCGCCCCCGCCCG]-CCATTCTATCTCCAATAACACCC TAA-3 0 , which amplify a 240-bp product (positions 27085 to 27280). The nucleotide in bold indicates a mismatch. PCR and subsequent melting-curve analysis were carried out using the LightCycler (Roche Molecular Biochemicals, Switzerland), as previously described (Worm et al., 2001a) . The reaction mixtures (20 ml) contained 10 pmol of each primer, 3 mM MgCl 2 , 1 Â FastStart DNA Master SYBR Green I (Roche), and bisulphite-modified DNA (B50 ng). Reactions were started by initial denaturation at 951C for 10 min, followed by cycling at 951C for 10 s, 651C for 15 s, and 721C for 40 s.
MCA was performed immediately after amplification by measuring the fluorescence of SYBR Green I during a linear temperature transition from 70 to 951C at 0.11C/s. Fluorescence data were converted into melting peaks by the LightCycler software (ver. 3.39) by plotting the negative derivative of fluorescence over temperature vs. temperature (ÀdF/dT vs. T).
For subcloning and sequencing of individual APC alleles, a region of APC promoter 1A, containing 28 CpG sites from -306 to þ 117 relative to the transcription start site, was amplified using nested PCR and bisulphite-treated genomic DNA as a template. Outer primers were 5 0 -TTTTGATAATT TAGTGATTTGTAATGTAA-3 0 and 5 0 -CCATCTCCAATA CTACAATAAAAAAC-3 0 , and inner primers were 5 0 -TATT TAATATTATTGTTTTTTTGTGTTGT-3 0 and 5 0 -TCCAAT-ACTACAATAAAAAACTAAAAAAC-3 0 . Purified PCR products were subcloned using the TA Cloning Kit (Invitrogen). Individual clones were grown and DNA was prepared using the Spin Miniprep Kit (Qiagen). Sequencing in both directions was carried out with 33 P-end-labelled primers using the ThermoPrime Cycle Sequencing Kit (Amersham, Piscataway, NJ, USA).
RT-PCR
cDNA was synthesized from total RNA (2 mg) using random hexamers, oligo-dT primers, and Superscript III (Invitrogen). Subsequent PCR analysis was carried out using a block thermocycler (GeneAmp PCR System 9600; Perkin-Elmer). A transcript initiated from APC promoter 1A was amplified using primers 5 0 -GAGACAGAATGGAGGTGCTGC-3 0 and 5 0 -GCCTCAGTTTCCAGTTTTGTAAGA-3 0 , which amplify a 177-bp product. Combined transcripts from promoters 1A and 1B were amplified using primers 5 0 -GCTTTGACAAACTT GACTTTTGGAG-3 0 and 5 0 -CAATACGCTTTTGAGGGTT GATTC-3 0 , to generate a 258-bp product from exon 11 to exon 14. As a control, RT-PCR of the housekeeping gene GAPDH was performed as described previously (Worm et al., 2001b) .
RQ-PCR
RQ-PCR was carried out using the LightCycler (Roche). Reaction mixtures (20 ml) contained 10 pmol of each primer, 3 mM MgCl 2 , 1 Â FastStart DNA Master SYBR Green I (Roche), and cDNA. The primer sequences were 5 0 -GCATT-GATGGAATGTGCTTTAGAA-3 0 and 5 0 -CAATACGCTTT TGAGGGTTGATTC-3 0 for APC, 5 0 -CCTGGGCCACTT-TAAGAGCA-3 0 and 5 0 -GCCTTCATACATCGGGAGCAC-3 0 for Axin2, 5 0 -GGGGAGCAGGCTGAAGGGT-3 0 and 5 0 -TGGAGAAGATCAGCCGGCGT-3 0 for p21, and 5 0 -TCCA AGCGGAGCCATGTCTG-3 0 and 5 0 -AGAATCTTGTCCC CTGTGGTGGA-3 0 for PBGD. Reactions were started by initial denaturation at 951C for 10 min, followed by cycling at 951C for 10 s, 651C (APC), 701C (Axin2 and p21) or 721C (PBGD) for 15 s, and 721C for 40 s.
Mutation analysis of the APC and CTNNB1 genes Exon 3 of the CTNNB1 gene and the entire coding sequence and all splice sites of the APC gene (exons 1-15) were scanned for mutations using a combination of PCR and DGGE. The melting characteristics of each exonic region were calculated by means of the MELT87 computer algorithm (Lerman and Silverstein, 1987) , and appropriate GC and AT clamps were included in the PCR primers to modulate the melting properties into a two-domain profile. The sequences of the 54 sets of primers for mutation analysis of APC are available on request. Primer sequences for CTNNB1 exon 3 were 5 0 -GTTTCGTATTTATAGCTGATTTG-3 0 and 5 0 -[CGCCCGC CGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCG]-TA AGGCAATGAAAAATAATACTC-3 0 , which generate a 310-bp product. PCR was carried out at an annealing temperature of 551C, using the HotStarTaq Kit (Qiagen). A measure of 10 ml of the GC-clamped product was loaded onto a 10% denaturant/6% polyacrylamide-70% denaturant/12% polyacrylamide double-gradient gel as described (Cremonesi et al., 1997) . The gels were run at 160 V for 6 h or overnight at 80 V in 1 Â TAE buffer kept at a constant temperature of 561C, stained in 1 Â TAE buffer containing ethidium bromide (2 mg/ ml), and photographed under UV transillumination. Direct sequencing of double-stranded PCR products was performed with a 33 P-end-labelled primer using the ThermoPrime Cycle Sequencing Kit (Amersham).
Immunoblotting
Cell lysates were prepared in a lysis buffer containing 50 mM Tris-HCl pH 7.6, 1% NP-40, 150 mM NaCl, 1 mM MgCl 2 , and a mixture of protease inhibitors (2 mg/ml each of leupeptin and aprotinin (Sigma, St Louis, MO, USA), 1 mg/ml of pepstatin A (Sigma, St Louis, MO, USA), and 200 mg/ml of Pefabloc (Roche)). Total protein content was determined using Coomassie Plus Protein Assay Reagent (Pierce, Rockford, IL, USA). Lysate corresponding to 100 mg of total protein was subjected to PAGE using 3-8% gradient gels (Invitrogen). Proteins were transferred to nitrocellulose in transfer buffer (Invitrogen) at 30 V for 2 h. APC was detected using two different primary anti-APC monoclonal antibodies, secondary antibodies coupled to HRP (DAKO, Glostrup, Denmark), and SuperSignal West Pico (Pierce). Anti-N-APC ab58 (Abcam, Cambridge, UK) was used at 0.5 mg/ml, and anti-N-APC F-3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used at 2.0 mg/ml. b-Catenin was detected using a monoclonal anti-b-catenin antibody, C19220 (BD Transduction Laboratories, Lexington, KY, USA), at 0.125 mg/ml.
Tcf reporter assay
Cells plated at 2 Â 10 6 /60-mm-diameter dish were transfected with 3 mg of either pTOPFLASH or pFOPFLASH reporter plasmid Korinek et al. (1997) and 0.5 mg of a vector containing an SV40 promoter-driven b-galactosidase gene as a control for transfection efficiency, using electroporation (BIO-RAD Gene Pulsert). Luciferase activity was measured in a luminometer (Berthold Lumat LB9501) 48 h after transfection. Data were normalized to the transfection efficiency by measuring the b-galactosidase activity.
RNAi
The pSUPER vector was a kind gift of Dr Reuven Agami (The Netherlands Cancer Institute), and has been described elsewhere (Brummelkamp et al., 2002) . For stable shRNA expression, we modified pSUPER by ligating a PmeI, AflIII restriction fragment of pcDNA3.1 (Invitrogen) containing the neomycin resistance gene into the pSUPER vector digested with HincII and AflIII (pSUPER/G418 R ). The sequence targeting APC (shRNA-APC) was formed from duplex DNA consisting of 5 0 -gatccccGCTCTGCTGCCCATACACAttcaagagaTGTGTATG GGCAGCAGAGCtttttggaaa-3 0 and 5 0 -agcttttccaaaaaGCTCT GCTGCCCATACACAtctcttgaaTGTGTATGGGCAGCAGA GCggg-3 0 . A mismatch control (mis-shRNA-APC) was formed from duplex DNA consisting of 5 0 -gatccccGCTCTGCTCGCCATACACAttcaagagaTGTGTATGGCGAGCAGAGCtttttg gaaa-3 0 and 5 0 -agcttttccaaaaaGCTCTGCTCGCCATACACAtctcttgaaTGTGTATGGCGAGCAGAGCggg-3 0 . Cells plated at 1 Â 10 6 /wells in six-well plates were transfected with 2 mg of the shRNA-APC or mis-shRNA-APC constructs, using Lipofectamine 2000 (Invitrogen). Stable clones were selected by the use of Geniticint (Invitrogen).
Proliferation rate
Cells were plated in 96-well microtitre plates at a density of 2500 cells/well in 0.1 ml of standard medium. In a 4-day schedule, cell number was estimated at eight time points using the Cell Proliferation Reagent WST-1 (Roche). After incubation with 10 ml of WST-1 for 3 h, the absorbance at 440 nm of the formazan dye was quantified using a scanning multichannel spectrophotometer (ELISA reader). The logarithm of the absorbance plotted against time yielded a straight line and the doubling time was calculated.
Invasive growth in collagen I
A collagen I mixture containing 2 mg/ml collagen I (Vitrogen, The Netherlands), 1 Â DMEM, 2.4 mg/ml NaHCO 3 , 20 mM Hepes pH 7.4, penicillin, and streptomycin was prepared on ice. A measure of 300 ml of this mixture was placed in each well in 48-well plates and left for 1 h to solidify at 371C in a 5% CO 2 incubator. Another 300 ml of the gel mixture was added to each well and left to solidify for 25 min. Finally, 300 ml gel mixture containing 10 000 cells was added to each well and left to solidify for 1 h and then covered with RPMI 1640 medium supplemented with 10% fetal bovine serum. The medium was replaced every second day, and after 14 days the cultures were evaluated for invasive growth.
